Walvax Biotechnology
Walvax Biotechnology Co Ltd is a Chinese biopharmaceutical enterprise manufacturing human vaccines for infectious diseases. The company develops and manufactures pediatric and adult vaccines, including 13-valent pneumococcal conjugate vaccines (PCV13), Haemophilus influenzae type b (Hib) vaccines, and human papillomavirus (HPV) vaccines. Principal revenues derive from direct product sales of human vaccines to provincial and municipal centers for disease control and prevention (CDCs) across China and international export markets. Core end markets encompass public health disease control agencies, pediatric immunization programs, and clinical vaccination centers in China, Asia, and South America. Walvax Biotechnology holds a market-leading domestic position in China as a premier private manufacturer of pediatric bacterial and viral vaccines. The company is headquartered in Kunming, China, and its common shares trade on the ChiNext board of the Shenzhen Stock Exchange.
2 of the funds FundTelligence covers report a position in Walvax Biotechnology.
- Legal name
- Walvax Biotechnology Co Ltd
- Sector
- Health Care
- Country
- China
- Funds holding it
- 2
Funds holding Walvax Biotechnology
- Handelsbanken Emerging Markets Index — Handelsbanken · 0.02 % (full portfolio disclosed, September 2026)
- Handelsbanken Global Index Criteria — Handelsbanken · 0.01 % (full portfolio disclosed, September 2026)